Generate Biomedicines targets 425 million dollars in US initial public offering
Drug developer Generate Biomedicines announced its plans on Monday to raise 425 million dollars. The firm is seeking an initial public offering within the US.
Generate Biomedicines announced on February 23, 2026, that it aims to raise as much as $425 million in an initial public offering in the United States 
US. The announcement marks a planned capital raise through the company's entry into U.S. public markets, representing a significant development for the entity.
US. The announcement marks a planned capital raise through the company's entry into U.S. public markets, representing a significant development for the entity.The filing is considered material because of the substantial size of the proposed $425 million raise and the selection of the U.S. market as the venue for the offering. This announcement, made today, highlights the company's intention to secure funding through a public listing.
